Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 0.72 |
| ▸ | DRD4 | P21917 | 3/20 | 0.72 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.66 |
| ▸ | CA1 | P00915 | 3/20 | 0.64 |
| ▸ | CA2 | P00918 | 3/20 | 0.64 |
| ▸ | ACHE | P22303 | 3/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.58 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15474018 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL3320662 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL29354627 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL338733 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL5143976 | 0.93 | DRD2 (0.86) | DRD2DRD3DRD4GRIN2BCA1 | |
| SCHEMBL8074250 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| SCHEMBL7543711 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| SCHEMBL8074280 | 0.91 | DRD2 (0.83) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| Hydrochloric Acid SCHEMBL7932989 | 0.90 | DRD2 (0.81) | DRD2DRD3DRD4GRIN2BMTNR1A | |
| Hydrochloric Acid SCHEMBL8604442 | 0.90 | DRD2 (0.81) | DRD2DRD3DRD4GRIN2BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113969303-A | Preparation method of rotigotine intermediate | 上海天慈国际药业有限公司 | 2022-01-25 | — | — | CN | claimed |
| CN-113969303-A | Preparation method of rotigotine intermediate | 上海天慈国际药业有限公司 | 2022-01-25 | — | — | CN | disclosed |
| CN-113969303-A | Preparation method of rotigotine intermediate | 上海天慈国际药业有限公司 | 2022-01-25 | — | — | CN | disclosed |
| US-8604242-B2 | Process for the preparation of optically active (S)-(−)-2-(N-propylamino)-5-methoxytetraline and (S)-(−)-2-(N-propylamino)-5-hydroxytetraline compounds | INTERQUIM, S.A. (ES) | 2013-12-10 | — | — | US | disclosed |
| EP-2346811-B1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS | INTERQUIM SA (ES) | 2012-08-15 | — | — | EP | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-8236845-B2 | Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-08-07 | — | — | US | disclosed |
| US-8097641-B2 | Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| US-8097641-B2 | Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| US-8097641-B2 | Heterocyclyl substituted tetrahydronaphthalene derivatives as 5-HT7 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2012-01-17 | — | — | US | disclosed |
| WO-2010043571-A1 | PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE (S)-(-)-2-(N-PROPYLAMINO)-5-METHOXYTETRALINE AND (S)-(-)-2-(N-PROPYLAMINO)-5-HYDROXYTETRALINE COMPOUNDS | INTERQUIM, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-11 | — | — | US | disclosed |
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-11 | — | — | US | disclosed |
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-02-11 | — | — | US | disclosed |
| WO-2008145335-A1 | COMBINATION OF A 5HT7 RECEPTOR LIGAND AND AN OPIOID RECEPTOR LIGAND | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-12-04 | — | — | WO | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997493-A1 | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand | Laboratorios del Dr. Esteve S.A. (ES) | 2008-12-03 | — | — | EP | disclosed |
| WO-2008095689-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-08-14 | — | — | WO | disclosed |
| EP-1956006-A1 | Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
| EP-1956006-A1 | Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands | Laboratorios del Dr. Esteve S.A. (ES) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035936-A1 | HETEROCYCLYL SUBSTITUTED TETRAHYDRONAPHTHALENE DERIVATIVES AS 5-HT7 RECEPTOR LIGANDS | HTR7, HTR2C, HTR6 | DRD2 264/4885DRD3 370/4885DRD4 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.